Natera

Natera R&D per Employee

The R&D Spending per Employee of Natera (NTRA) as of Oct 12, 2026 is 101,729.42 USD. In the previous year, R&D Spending per Employee was 65,874.16 USD — a change of 54.43% (higher).

R&D per Employee

101,729.42USD

YoY

54.43%

Last updated:

R&D Spending per Employee of Natera is 2025 101,729.42 USD. R&D Spending per Employee of Natera was 2024 65,874.16 USD. It decreases by 54.43% higher compared to the previous year.

The Natera R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
8,370.82 USD
Jan 1, 2019
8,371.15 USD
Jan 1, 2020
16,305.62 USD
Jan 1, 2021
43,065.69 USD
Jan 1, 2022
51,575.39 USD
Jan 1, 2023
52,270.25 USD
Jan 1, 2024
65,874.16 USD
Jan 1, 2025
101,729.42 USD
The Natera R&D per Employee history
YEARR&D per EmployeeYoY
101,729.42USD+54.43%
65,874.16USD+26.03%
52,270.25USD+1.35%
51,575.39USD+19.76%
43,065.69USD+164.12%
16,305.62USD+94.78%
8,371.15USD+0.00%
8,370.82USD+2.58%
8,160.39USD+19.59%
6,823.47USD+51.07%
4,516.87USD+60.25%
2,818.58USD—
Access this data via the Eulerpool API

Natera Stock analysis

What does Natera do? Natera Inc. is an American company headquartered in San Carlos, California. It was founded in 2004 by Matthew Rabinowitz and has been listed on the NASDAQ under the ticker symbol "NTRA" since 2015. The company is a leading provider of diagnostic tests and analyses and specializes in genetic analysis and diagnostic technologies. Natera specializes in tests for various medical areas, particularly in oncology diagnostics. The company's vision is to improve the quality of life for millions of people worldwide by offering innovative diagnostic tests to detect diseases early and ensure optimal treatment. Natera offers a wide range of products tailored to the needs of consumers, physicians, and scientists. The company operates in three business areas: 1) Women's Health: Natera offers tests for women and couples to determine the risk of hereditary diseases. For example, the company offers a test that allows analysis of fetal DNA from the mother's blood, allowing detection of genetic abnormalities in the fetus before birth. Additionally, Natera offers the Panorama test, which provides tests for genetic anomalies in unborn babies that can be used to determine the risk for chromosomal abnormalities and genetic mutations. 2) Oncology: In the field of oncology, Natera offers a wide range of diagnostic tests targeting developments and trends in cancer research. The tests aim to enable accurate diagnosis and prognosis, as well as provide individualized treatment for each patient. The company offers tests that assess the current tumor growth and metastatic potential, enable determination of tumor burden in cells, and provide tests for specific mutations required for determining optimal treatment. 3) Genomic Analysis: In the field of genomic analysis, Natera offers a broad range of tests available to researchers and scientists. This includes genetic variants and biological mechanisms that cause diseases. The company is also committed to developing its tests through artificial intelligence (AI) and machine learning. The goal is to provide more accurate and faster results, improve clinical decisions, and advance research and development of new diagnostics. Conclusion: Natera is a leading company in the field of diagnostic tests and analyses in the field of genomic analysis. The company has a long history of research and development of innovative product solutions for the medical community. One important focus of the company is to improve women's health and be able to detect risks for genetic diseases early; the other focus is on oncology diagnostic tools to determine optimal treatment for cancer patients. The company is constantly striving to further develop its tests and integrate new research findings and technologies to support the medical science community. Natera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Natera stock

R&D Spending per Employee of Natera is 101,729.42 USD in 2025.

R&D Spending per Employee of Natera changed from 65,874.16 USD to 101,729.42 USD, representing a 54.43% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Natera since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Natera historically and in real time.

Access this data via the Eulerpool API

Workforce — Natera

All Key Metrics — Natera